Integrating Innate Immunity into a Global “Systems” Context: The Complement Paradigm Shift - Systems Biology: Networks, Models, and Applications - page 187

42. Morikis, D., M. Roy, A. Sahu, et al. The structural basis of compstatin activ-

ity examined by structure-function-based design of peptide analogs and
NMR. Journal of Biological Chemistry , 277(17):14942-53, 2002.

43. Klepeis, J. L., C. A. Floudas, D. Morikis, et al. Integrated computational

and experimental approach for lead optimization and design of compstatin
variants with improved activity. Journal of the American Chemical Society ,
125(28):8422-3, 2003.

44. Klepeis, J. L., C. A. Floudas, D. Morikis and J. D. Lambris. Predicting

peptide structures using NMR data and deterministic global optimization.
Journal of Computational Chemistry , 20:1354-70, 1999.

45. Klepeis, J. L. and C. A. Floudas. Ab initio tertiary structure prediction of

proteins. Journal of Global Optimization , 25:113-40, 2003.

46. Klepeis, J. L., H. D. Schafroth, K. M. Westerberg, et al. Deterministic global

optimization and ab initio approaches for the structure prediction of
polypeptides, dynamics of protein folding, and protein-protein interactions.
Computational Methods for Protein Folding-Advances in Chemical Physics ,
120:265-457, 2002.

47. Chong, S., G. E. Montello, A. Zhang, et al. Utilizing the C-terminal cleav-

age activity of a protein splicing element to purify recombinant proteins in
a single chromatographic step. Nucleic Acids Research , 26(22):5109-15, 1998.

48. Mallik, B., M. Katragadda, L. A. Spruce, et al. Design and NMR character-

ization of active analogues of compstatin containing non-natural amino
acids. Journal of Medicinal Chemistry , 48(1):274-86, 2005.

49. Mallik, B., J. D. Lambris and D. Morikis. Conformational interconversion

in compstatin probed with molecular dynamics simulations. Proteins ,
53(1):130-41, 2003.

50. Paczkowski, N. J., A. M. Finch, J. B. Whitmore, et al. Pharmacological

characterization of antagonists of the C5a receptor. British Journal of
Pharmacology , 128(7):1461-6, 1999.

51. Morikis, D. and J. D. Lambris. Structural aspects and design of low-

molecular-mass complement inhibitors. Biochemical Society Transactions ,
30(6):1026-36, 2002.

52. Huber-Lang, M. S., N. C. Riedeman, J. V. Sarma, et al. Protection of innate

immunity by C5aR antagonist in septic mice. FASEB Journal ,
16(12):1567-74, 2002.

53. Strey, C. W., M. Markiewski, D. Mastellos, et al. The proinflammatory

mediators C3a and C5a are essential for liver regeneration. Journal of
Experimental Medicine , 198(6):913-23, 2003.

54. Girardi, G., J. Berman, P. Redecha, et al. Complement C5a receptors and

neutrophils mediate fetal injury in the antiphospholipid syndrome. Journal
of Clinical Investigation , 112(11):1644-54, 2003.

55. Kim, A. H., I. D. Dimitriou, M. C. Holland, et al. Complement C5a recep-

tor is essential for the optimal generation of antiviral CD8 + T cell

responses. Journal of Immunology, 173(4):2524-9, 2004.

56. Pennington, S. R., M. R. Wilkins, D. F. Hochstrasser, et al. Proteome analy-

sis: from protein characterization to biological function. Trends in Cell
Biology , 7(1):168-73, 1997.

57. Anderson, L. and J. Seilhamer. A comparison of selected mRNA and

protein abundances in human liver. Electrophoresis , 18(3-4):533-7, 1997.